Title : Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.

Pub. Date : 2019 Nov 15

PMID : 31320594






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia. midostaurin BCL2 apoptosis regulator Homo sapiens
2 In vivo results show that gilteritinib in combination with venetoclax has therapeutic potential.Conclusions: Inhibition of Bcl-2 via venetoclax synergistically enhances the efficacy of midostaurin and gilteritinib in FLT3-mutated AML. midostaurin BCL2 apoptosis regulator Homo sapiens